Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Cavo, Michèle; Pantani, Lucia; Teresa Petrucci, Maria; Patriarca, Francesca; Zamagni, Elena; Donnarumma, Daniela; Crippa, Claudia; Boccadoro, Mario; Perrone, Giulia; Falcone, Antonietta; Nozzoli, Chiara; Zambello, Renato; Masini, Luciano; Furlan, Anna; Brioli, Annamaria; Derudas, Daniele; Ballanti, Stelvio; Laura Dessanti, Maria; De Stefano, Valerio; Michele Carella, Angelo; Marcatti, Magda; Nozza, Andrea; Ferrara, Felicetto; Callea, Vincenzo; Califano, Catello; Pezzi, Annalisa; Baraldi, Anna; Grasso, Mariella; Musto, Pellegrino; Palumbo, Antonio

doi:10.1182/blood-2012-02-408898

Public

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Published in Blood • Apr 13, 2012

Authors:

Michèle Cavo

Lucia Pantani

Maria Teresa Petrucci

Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologo...

Subject

Medicine

Thalidomide

Bortezomib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!